flow trial semaglutide kidney outcomes 2024 Effects of With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Disease: A Prespecified Secondary Analysis ❇️Patients with obesity, type 2

GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing digestion and reducing appetite

OLeary et al., using diagnostic codes, found that GLP-1 RA (exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, tirzepatide) use was associated with a reduction in the odds of visual loss: at 6 months, OR 0.423 (95% CI 0.3240.546), and at 1 year, OR 0.606 (0.4890.747), compared to matched controls [37]

it requires coordination between your weight-loss provider (who prescribed your PlexusDx medication), your primary care physician, and your fertility specialist or obstetrician

[DOI] [PubMed] [Google Scholar] 233.Lebrun, L

534, no

Liu X, Zhang Y, Zheng S-Y, et al